GT Biopharma effects 1-for-25 reverse stock split, cuts authorized shares to 26.5M

GT Biopharma, Inc.

Reverse split effective 12:01 a.m. ET Sept 8, 2026; trading on split-adjusted basis begins at market open.
Outstanding shares drop from ~45,109,497 to ~1,804,379; no fractional shares, cash paid for fractions.
Authorized capital reduced from 265M to 26.5M shares (25M common, 1.5M preferred); new CUSIP 36254L407.
Certificates of Elimination filed for Series A-K preferred; all Series C converted, no other preferred outstanding.
Board approved 1-for-25 ratio on Aug 27, 2026, following stockholder authorization at Aug 14 meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.